Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
Andreas Reiter, Jason Gotlib, Iván Álvarez‐Twöse, et al.
Leukemia (2022) Vol. 36, Iss. 8, pp. 2108-2120
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

The international consensus classification of eosinophilic disorders and systemic mastocytosis
Sa A. Wang, Attilio Orazi, Jason Gotlib, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1286-1306
Closed Access | Times Cited: 28
Avapritinib for advanced systemic mastocytosis
Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo
Blood (2022) Vol. 140, Iss. 15, pp. 1667-1673
Closed Access | Times Cited: 27
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Johannes Lübke, Deborah Christen, Juliana Schwaab, et al.
Leukemia (2024) Vol. 38, Iss. 4, pp. 810-821
Open Access | Times Cited: 5
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
Donal P. McLornan, Tomasz Czerw, Gandhi Damaj, et al.
Leukemia (2024)
Closed Access | Times Cited: 5
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms
Jason Gotlib
Hematology (2022) Vol. 2022, Iss. 1, pp. 34-46
Open Access | Times Cited: 20
World Health Organization Classification and Diagnosis of Mastocytosis
Peter Valent, Karl Sotlar, Hans‐Peter Horny, et al.
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 627-649
Closed Access | Times Cited: 11
A post‐marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database
Li Rong, Mengyuan Xie, Manxue Jiang, et al.
British Journal of Clinical Pharmacology (2023) Vol. 90, Iss. 8, pp. 1816-1826
Closed Access | Times Cited: 9
KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
Marcelo A. S. Toledo, Xu‐Huang Fu, Tiago Maié, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5275-5275
Open Access | Times Cited: 8
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
Johannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Annals of Hematology (2023) Vol. 102, Iss. 8, pp. 2077-2085
Open Access | Times Cited: 8
KIT Mutations and Other Genetic Defects in Mastocytosis
Yannick Chantran, Peter Valent, Michel Arock
Immunology and Allergy Clinics of North America (2023) Vol. 43, Iss. 4, pp. 651-664
Open Access | Times Cited: 8
Transcriptional regulation of DLGAP5 by AR suppresses p53 signaling and inhibits CD8+ T cell infiltration in triple-negative breast cancer
Qing Pan, Dachang Ma, Yi Xiao, et al.
Translational Oncology (2024) Vol. 49, pp. 102081-102081
Open Access | Times Cited: 2
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
Peter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 6, pp. 1706-1717
Open Access | Times Cited: 5
Recent advances in diagnosis and therapy in systemic mastocytosis
Hyun Jung Lee
Blood Research (2023) Vol. 58, Iss. S1, pp. S96-S108
Open Access | Times Cited: 4
Beyond Midostaurin: Role of Avapritinib in Managing Systemic Mastocytosis
Ngowari Pokima, Georges Khattar, Praneeth Reddy Keesari, et al.
Cureus (2024)
Open Access | Times Cited: 1
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases
Ayalew Tefferi, Maymona Abdelmagid, Aref Al‐Kali, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 1, pp. 21-27
Closed Access | Times Cited: 3
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
Peter Valent, Cem Akin, Michel Arock, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15125-15125
Open Access | Times Cited: 2
Лечение агрессивного системного мастоцитоза и тучноклеточного лейкоза. Обзор литературы и серия клинических наблюдений
В. Г. Потапенко, З. К. Абдулхаликова, В В Байков, et al.
Clinical oncohematology (2024) Vol. 17, Iss. 2, pp. 180-194
Open Access
Nouveaux critères diagnostiques des mastocytoses : des progrès mais encore des interrogations
Michel Arock
Bulletin de l Académie Nationale de Médecine (2024) Vol. 208, Iss. 6, pp. 810-823
Closed Access
Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronyltransferase (UGT) 1A1
Xin Lv, Zhen Wang, Zhe Wang, et al.
Current Drug Metabolism (2024) Vol. 25, Iss. 3, pp. 197-204
Closed Access
SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis
Helen T. Chifotides, Prithviraj Bose
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow
Do H. Kim, Fuli Jia, Keyur P. Patel, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 11, pp. e878-e882
Open Access
Management of Advanced Systemic Mastocytosis: Clinical Challenges
Douglas Tremblay, Nicole Wagner, John O. Mascarenhas
Journal of Blood Medicine (2024) Vol. Volume 15, pp. 421-433
Open Access
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin
Maël Heiblig, C. Gourguechon, Philippe Guilpain, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 11, pp. 2127-2139
Open Access
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
Francesco Mannelli, Francesca Crupi, Roberta Zanotti, et al.
Therapeutic Advances in Hematology (2023) Vol. 14
Open Access | Times Cited: 1
Mastocytosis demystified
Scott Veitch, Deepti Radia
Hematology (2023) Vol. 2023, Iss. 1, pp. 396-406
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top